The insomnia drug Lunesta (eszopiclone) can linger in users’ bloodstreams hours longer than intended, causing impairment of driving and other activities that require alertness, the Food and Drug Administration warned. The agency is recommending that starting doses be lowered to 1 mg at bedtime for both men and women. The drug labels for Lunesta and its generic counterparts will be updated to reflect the new warnings and recommended dosing. The new dosing is based on a study that found that the previously recommended dose of 3 mg can cause impairment of driving skills, memory and coordination that can last more ... Read More
Righting Injustice is published by the Beasley Allen Law Firm. If you are interested in a free legal consultation, please take a few moments to fill out the contact form with as many details as possible. The more information you provide us, the better we can evaluate your claim.